X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effect. It is being evaluated for the treatment of schizophrenia.
Lead Product(s): AF710B
Therapeutic Area: Psychiatry/Psychology Product Name: AF710B
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effect. It is being evaluated in phase 1 clinical trials for the treatment of schizophrenia.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: ANAVEX 3-71
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
ANAVEX®3-71 (AF710B), which targets sigma-1 and M1 muscarinic receptors, promising clinical stage drug candidate demonstrating disease-modifying activity against major hallmarks of AD in transgenic mice, including cognitive deficits, amyloid, and tau pathologies.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: Anavex3-71
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Study reached primary and secondary endpoints of safety for ANAVEX®3-71, which was found to be well tolerated as oral administration in all dose cohorts with No serious adverse events or dose-limiting toxicities observed.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: ANAVEX3-71
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
Enrollment of the first participant has began in a Phase 1 clinical trial of ANAVEX®3-71, an orally-administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: AF710B
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
ANAVEX3-71 demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: AF710B
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
Anavex got approval from Australian Human Research Ethics Committee has to initiate the First-in-Human FIH clinical study of ANAVEX®3-71 (AF710B), a small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: AF710B
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
